Silo Pharma, Inc. · NASDAQ:SILO
Silo Pharma — Investor Presentation (June 2022)
19 slides from Silo Pharma's investor presentation, Jun 1, 2022
Slide 1: Spring 2022 Corporate Presentation
Spring 2022 Corporate Presentation OCTQB: SILO
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains "forward-looking statements" within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expec
Slide 3: Silo Pharma At a Glance
Silo Pharma At a Glance Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. We are committed to developing innovative solutions to address a variety of underserved conditions, including Alzheimer’s, Parkinson's Multipl
Slide 4: The Silo Difference
The Silo Difference ▪ While partnering with some of the leading Academic Institutions Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505 (b)(2) route for trials. ▪ Silo anticipates this strategy will lower cost and allow for a faster approval process to hel
Slide 5: The Silo Advantage
Growing Pipeline of Gaining Regulatory Opportunities Support The Silo ▪ Psychedelic drugs have shown encouraging promise ▪ Silo has a faster FDA pathway utilizing 505b Advantage ▪ Licensing and funding research pathway with various therapeutics in its pipeline with transformative potential Subtitle
Slide 6: Scientific Advisory Board
Scientific Advisory Board Josh Woolley, M.D., Ph.D. Dr. Woolley is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF). He is also a licensed psychiatrist on staff at the San Francisco Veterans Affairs Medical Center (S
Slide 7: SPC-14: Targeting Alzheimer's
Market Opportunity: Regulatory Pathway Alzheimer’s Disease and Results SPC-14 ▪ 6.5 million of Americans suffer from Alzheimer’s and related ▪ ▪ 505b Pathway Preclinical testing and POC Targeting ▪ diseases ~1 in 9 Americans 65+ have being lead by inventor Dr. Christine Denny of Alzheimer's Alzheime
Slide 8: SPU-16: CNS Homing Peptide for Multiple Sclerosis
Market Opportunity: Regulatory Pathway and Multiple Sclerosis (MS) Results 505b Pathway SPU-16 ▪ There are approximately 400,000 Americans and 2.5 million people ▪ May be used as a delivery tool to target current therapies to CNS Homing ▪ worldwide with MS The most widespread disabling detect inflam
Slide 9: SPU-21: Arthritogenic Joint Homing Peptides
Market Opportunity: Applications Rheumatoid Arthritis (RA) ▪ Identify markers of arthritic SPU-21 ▪ ▪ 1.3M U.S. adults suffer from RA The most common ▪ inflammation in joints Isolate phage clones that Arthritogenic ▪ autoimmune disease in U.S. U.S. market for RA drugs preferentially target inflamed
Slide 10: SPC-15: Stress-Induced Affective Disorders
Market Opportunity: Applications Stress-induced Affective ▪ Sponsored Research Disorders SPC-15 ▪ 26% of Americans 18+ suffer Agreement with Columbia University Prevention of stress- Targeted from anxiety, PTSD and other induced affective disorders disorders ▪ Increasing stress resilience in prophyl
Slide 11: SPC-26: Time-Released Psilocybin, Ketamine
SPC-26 Market Opportunity: Applications Time-Released ▪ Deliver Ketamine or Psilocybin ▪ Multiple Indications Psilocybin, in a time-released manner ▪ Will time-release diminish the Ketamine hallucinogenic effects of these Technology psychedelics ▪ Pre clinical study underway Joint Venture ▪ Joint Ve
Slide 12: Clinical Study I: Ketamine & Psilocybin on Parkinson's Disease
Market Opportunity: Applications Parkinson’s Disease Clinical 1.2M Americans expected to ▪ Better awareness of cognitive ▪ and emotional dysfunctions in Study I: have Parkinson’s Disease by 2030 Parkinson’s disease ▪ Gain understanding of Repeated ▪ Parkinson’s growing by 50% repeated low doses of i
Slide 13: Clinical Study II: Effect of Psilocybin on Inflammation in the Blood
Clinical Study II: Market Opportunity: Applications Effect of Multiple Indications ▪ Examine psilocybin’s and Psilocybin on ▪ Parkinson’s Disease, chronic pain, and bipolar disorder. ketamine’s effect on inflammatory activity in Inflammation humans in the Blood ▪ Accelerate its implementation as a p
Slide 14: Silo's Development Timeline
Silo’s Development Timeline Optimization/ Drug Indication Preclinical Phase I Phase II Phase III Launch Next Milestone Proof of Concept Data expected in SPC-14 Alzheimer’s Summer 2022 Data on arthritic tissue study expected in June SPU-16 Multiple Sclerosis (MS) 2022 Rheumatoid Arthritis Drug at CRO
Slide 15: Intellectual Property
Intellectual Property Patents issued and provisional US Patent issued 11/16/21 #11174287 Central Nervous System Homing Peptides US #8,623,377 Joint-Homing peptide U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin,” filed August 3, 2020 U.S. Pro
Slide 16: Directors & Director Nominees
Directors & Director Nominees Wayne Linsley, Director Mr. Linsley has served as an independent director of the Company since January 2020. Has a bachelor’s in business administration from Siena College in Loudonville, NY. From 2009 to September 2021, he worked for a financial reporting firm that wor
Slide 17: Executive Leaders
Executive Leaders Eric Weisblum, CEO Mr. Weisblum has over 20 years investing, building and managing businesses. Will lead a scientific advisory board of reputable medical professionals to work and guide the company through the different stages of research, licensing, partnerships and trials. Prior,
Slide 18: Investment Considerations
Investment Considerations Established collaborations Multiple large disease Strong intellectual with leading academic markets being property position institutions pursued Experienced Well- Pursuing up drug capitalized listing to development balance sheet Nasdaq team
Slide 19: Thank you
thank you. Eric Weisblum 560 Sylvan Ave, Suite 3160 Englewood Cliffs, NJ 07632 [email protected]